NCT03641313 2026-04-13
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
6 trialsNCT05078866 2026-03-03
Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT04929392 2025-09-04
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT02911142 2025-07-28
Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting
NCT04864067 2025-07-01
NOAHS-ARC
Servicio de Salud Metropolitano Sur Oriente
Phase 2 Active not recruiting
NCT04454476 2024-07-31
Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor
Vanderbilt-Ingram Cancer Center
Phase 1 Active not recruiting